Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer

Molecular and Cellular Proteomics

Volumn 9, Issue 1, 2010, Pages 161-177

  Moreira, José M A ^a   Ohlsson, Gita ^a,c   Gromov, Pavel ^a   Simon, Ronald ^b   Sauter, Guido ^b   Celis, Julio E ^a   Gromova, Irina ^a  

^a Institute of Cancer Biolog   (Denmark)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BLADDER CANCER ASSOCIATED PROTEIN; FATTY ACID BINDING PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BENIGN BLADDER UROTHELIUM CARCINOMA; BLADDER CANCER; CELLULAR DISTRIBUTION; COHORT ANALYSIS; CONTROLLED STUDY; DEREGULATION; DISEASE SEVERITY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; TUMOR BIOPSY; TUMOR GROWTH; URINARY TRACT CARCINOMA; UROTHELIAL CARCINOMA; VALIDATION STUDY;

ANIMALS; BINDING SITES; BLOTTING, WESTERN; CERCOPITHECUS AETHIOPS; COS CELLS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PHOSPHORYLATION; PROGNOSIS; PROTEOMICS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 76649096335     PISSN: 15359476     EISSN: None     Source Type: Journal    
DOI: 10.1074/mcp.M900294-MCP200     Document Type: Article

References (64)

1. Parkin, D. M. (2008) The global burden of urinary bladder cancer. Scand. J. Urol. Nephrol. Suppl. 12-20
2. Pauli, B. U., Alroy, J., and Weinstein, R. S. (1983) in The Pathology of Bladder Cancer (Bryan, G. T., and Cohen, S. M., eds) Vol. II, pp. 41-140, CRC Press, Boca Raton, FL
3. Heney, N. M. (1992) Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol. Clin. North Am. 19, 429-433
4. Celis, J. E., and Gromov, P. (2003) Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 3, 9-15
5. Gromova, I., Gromov, P., and Celis, J. E. (1999) Identification of true differentially expressed mRNAs in a pair of human bladder transitional cell carcinomas using an improved differential display procedure. Electrophoresis 20, 241-248
6. Celis, J. E., Ostergaard, M., Basse, B., Celis, A., Lauridsen, J. B., Ratz, G. P., Andersen, I., Hein, B., Wolf, H., Orntoft, T. F., and Rasmussen, H. H. (1996) Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res. 56, 4782-4790
7. Ostergaard, M., Wolf, H., Orntoft, T. F., and Celis, J. E. (1999) Psoriasin (S100A7): a putative urinary marker for the follow-up of patients with bladder squamous cell carcinomas. Electrophoresis 20, 349-354
8. Gromova, I., Gromov, P., Wolf, H., and Celis, J. E. (1998) Protein abundancy and mRNA levels of the adipocyte type fatty acid binding protein correlate in non-invasive and invasive bladder transitional cell carcinomas. Int. J. Oncol. 13, 379-383
9. Celis, J. E., Celis, P., Palsdottir, H., Østergaard, M., Gromov, P., Primdahl, H., Ørntoft, T. F., Wolf, H., Celis, A., and Gromova, I. (2002) Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas. Mol. Cell. Proteomics 1, 269-279
10. Ostergaard, M., Rasmussen, H. H., Nielsen, H. V., Vorum, H., Orntoft, T. F., Wolf, H., and Celis, J. E. (1997) Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Res. 57, 4111-4117
11. Ohlsson, G., Moreira, J. M., Gromov, P., Sauter, G., and Celis, J. E. (2005) Loss of expression of the adipocyte-type fatty acid-binding protein (AFABP) is associated with progression of human urothelial carcinomas. Mol. Cell. Proteomics 4, 570-581
12. Moreira, J. M., Gromov, P., and Celis, J. E. (2004) Expression of the tumor suppressor protein 14-3-3σ is down-regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-to-mesenchymal transition. Mol. Cell. Proteomics 3, 410-419
13. Gromova, I., Gromov, P., and Celis, J. E. (2002) Bc10: a novel human bladder cancer-associated protein with a conserved genomic structure downregulated in invasive cancer. Int. J. Cancer 98, 539-546
14. Zuo, Z.H., Zhao, M., Liu, J., Wei, Y., and Wu, X. X. (2006) Inhibitory effect of bladder cancer related protein gene on HeLa cell proliferation. Ai Zheng 25, 811-817
15. Zuo, Z., Zhao, M., Liu, J., Gao, G., and Wu, X. (2006) Functional analysis of bladder cancer-related protein gene: a putative cervical cancer tumor suppressor gene in cervical carcinoma. Tumour Biol. 27, 221-226
16. Rae, F. K., Stephenson, S. A., Nicol, D. L., and Clements, J. A. (2000) Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display. Int. J. Cancer 88, 726-732
17. Yao, J., Duan, L., Fan, M., Yuan, J., and Wu, X. (2007) Overexpression of BLCAP induces S phase arrest and apoptosis independent of p53 and NF-kappaB in human tongue carcinoma: BLCAP overexpression induces S phase arrest and apoptosis. Mol. Cell. Biochem. 297, 81-92
18. Su, H. C., Zhao, Y. H., Fan, D. G., Fan, Q. Y., Zhang, P., Wen, Y. H., and Liu, Y. Y. (2003) Relationship between expression of BLCAP protein and malignancy of osteosarcoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 19, 465-466
19. Levanon, E. Y., Hallegger, M., Kinar, Y., Shemesh, R., Djinovic-Carugo, K., Rechavi, G., Jantsch, M. F., and Eisenberg, E. (2005) Evolutionarily conserved human targets of adenosine to inosine RNA editing. Nucleic Acids Res. 33, 1162-1168
20. Riedmann, E. M., Schopoff, S., Hartner, J. C., and Jantsch, M. F. (2008) Specificity of ADAR-mediated RNA editing in newly identified targets. RNA 14, 1110-1118
21. Brusa, R., Zimmermann, F., Koh, D. S., Feldmeyer, D., Gass, P., Seeburg, P. H., and Sprengel, R. (1995) Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice. Science 270, 1677-1680
22. Gurevich, I., Tamir, H., Arango, V., Dwork, A. J., Mann, J. J., and Schmauss, C. (2002) Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron 34, 349-356
23. Kawahara, Y., Ito, K., Sun, H., Aizawa, H., Kanazawa, I., and Kwak, S. (2004) Glutamate receptors: RNA editing and death of motor neurons. Nature 427, 801
24. Maas, S., Patt, S., Schrey, M., and Rich, A. (2001) Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc. Natl. Acad. Sci. U.S.A. 98, 14687-14692
25. Cenci, C., Barzotti, R., Galeano, F., Corbelli, S., Rota, R., Massimi, L., Di Rocco, C., O'Connell, M. A., and Gallo, A. (2008) Downregulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation. J. Biol. Chem. 283, 7251-7260
26. Paz, N., Levanon, E. Y., Amariglio, N., Heimberger, A. B., Ram, Z., Constantini, S., Barbash, Z. S., Adamsky, K., Safran, M., Hirschberg, A., Krupsky, M., Ben-Dov, I., Cazacu, S., Mikkelsen, T., Brodie, C., Eisenberg, E., and Rechavi, G. (2007) Altered adenosine-to-inosine RNA editing in human cancer. Genome Res. 17, 1586-1595
27. Sommer, B., Köhler, M., Sprengel, R., and Seeburg, P. H. (1991) RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell 67, 11-19
28. Burns, C. M., Chu, H., Rueter, S. M., Hutchinson, L. K., Canton, H., Sanders-Bush, E., and Emeson, R. B. (1997) Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 387, 303-308
29. Hoopengardner, B., Bhalla, T., Staber, C., and Reenan, R. (2003) Nervous system targets of RNA editing identified by comparative genomics. Science 301, 832-836
30. Zilberman, D. E., Safran, M., Paz, N., Amariglio, N., Simon, A., Fridman, E., Kleinmann, N., Ramon, J., and Rechavi, G. (2009) Does RNA editing play a role in the development of urinary bladder cancer? Urol Oncol., in press
31. Clutterbuck, D. R., Leroy, A., O'Connell, M. A., and Semple, C. A. (2005) A bioinformatic screen for novel A-I RNA editing sites reveals recoding editing in BC10. Bioinformatics 21, 2590-2595
32. Kwak, S., Nishimoto, Y., and Yamashita, T. (2008) Newly identified ADAR-mediated A-to-I editing positions as a tool for ALS research. RNA Biol. 5, 193-197
33. Bergkvist, A., Ljungqvist, A., and Moberger, G. (1965) Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years. Acta Chir. Scand. 130, 371-378
34. Celis, J. E., Gromova, I., Cabezón, T., Gromov, P., Shen, T., Timmermans-Wielenga, V., Rank, F., and Moreira, J. M. (2007) Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. Mol. Oncol. 1, 321-349
35. Richter, J., Wagner, U., Kononen, J., Fijan, A., Bruderer, J., Schmid, U., Ackermann, D., Maurer, R., Alund, G., Knönagel, H., Rist, M., Wilber, K., Anabitarte, M., Hering, F., Hardmeier, T., Schönenberger, A., Flury, R., Jäger, P., Fehr, J. L., Schraml, P., Moch, H., Mihatsch, M. J., Gasser, T., Kallioniemi, O. P., and Sauter, G. (2000) High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am. J. Pathol. 157, 787-794
36. Nocito, A., Bubendorf, L., Tinner, E. M., Süess, K., Wagner, U., Forster, T., Kononen, J., Fijan, A., Bruderer, J., Schmid, U., Ackermann, D., Maurer, R., Alund, G., Knönagel, H., Rist, M., Anabitarte, M., Hering, F., Hardmeier, T., Schoenenberger, A. J., Flury, R., Jäger, P., Fehr, J. L., Schraml, P., Moch, H., Mihatsch, M. J., Gasser, T., and Sauter, G. (2001) Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J. Pathol. 194, 349-357
37. International Union against Cancer (2002) in TNM Classification of Malignant Tumours (Sobin, L. H., and Wittekind, C., eds) 6th Ed., John Wiley and Sons, New York
38. Mostofi, F. (1973) in Histological Typing of Urinary Bladder Tumors, World Health Organization, Geneva
39. Celis, J. E., and Gromov, P. (2000) High-resolution two-dimensional gel electrophoresis and protein identification using western blotting and ECL detection. EXS 88, 55-67
40. Krogh, A., Larsson, B., von Heijne, G., and Sonnhammer, E. L. (2001) Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J. Mol. Biol. 305, 567-580
41. Kahsay, R. Y., Gao, G., and Liao, L. (2005) An improved hidden Markov model for transmembrane protein detection and topology prediction and its applications to complete genomes. Bioinformatics 21, 1853-1858
42. Blom, N., Gammeltoft, S., and Brunak, S. (1999) Sequence- and structure-based prediction of eukaryotic protein phosphorylation sites. J. Mol. Biol. 294, 1351-1362
43. Huang, H. D., Lee, T. Y., Tzeng, S. W., and Horng, J. T. (2005) KPhos: a web tool for identifying protein kinase-specific phosphorylation sites. Nucleic Acids Res. 33, W226-W229
44. Bendtsen, J. D., Nielsen, H., von Heijne, G., and Brunak, S. (2004) Improved prediction of signal peptides: SignalP 3.0. J. Mol. Biol. 340, 783-795
45. Petrova, T. V., Bono, P., Holnthoner, W., Chesnes, J., Pytowski, B., Sihto, H., Laakkonen, P., Heikkilä, P., Joensuu, H., and Alitalo, K. (2008) VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors. Cancer Cell 13, 554-556
46. Baluk, P., and McDonald, D. M. (2008) Markers for microscopic imaging of lymphangiogenesis and angiogenesis. Ann. N.Y. Acad. Sci. 1131, 1-12
47. Matsumoto, K., Soh, S., Satoh, T., Iwamura, M., Ishikawa, Y., Ishii, T., and Baba, S. (2008) Distribution of lymphatic vessel network in normal urinary bladder. Urology 72, 706-710
48. Sehested, M., and Hou-Jensen, K. (1981) Factor VII related antigen as an endothelial cell marker in benign and malignant diseases. Virchows Arch. A Pathol. Anat. Histol. 391, 217-225
49. Wang, S., Saboorian, M. H., Frenkel, E. P., Haley, B. B., Siddiqui, M. T., Gokaslan, S., Wians, F. H., Jr., Hynan, L., and Ashfaq, R. (2001) Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am. J. Clin. Pathol. 116, 495-503
50. Faith, D. A., Isaacs, W. B., Morgan, J. D., Fedor, H. L., Hicks, J. L., Mangold, L. A., Walsh, P. C., Partin, A. W., Platz, E. A., Luo, J., and De Marzo, A. M. (2004) Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate 61, 215-227
51. Clark, G. M. (2008) Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol. Oncol. 1, 406-412
52. Spector, D. L. (2001) Nuclear domains. J. Cell Sci. 114, 2891-2893
53. Spector, D. L. (2006) SnapShot: cellular bodies. Cell 127, 1071
54. Rosenblatt, R., Jonmarker, S., Lewensohn, R., Egevad, L., Sherif, A., Kälkner, K. M., Nilsson, S., Valdman, A., and Ullén, A. (2008) Current status of prognostic immunohistochemical markers for urothelial bladder cancer. Tumour Biol. 29, 311-322
55. Celis, J. E., Gromova, I., Moreira, J. M., Cabezon, T., and Gromov, P. (2004) Impact of proteomics on bladder cancer research. Pharmacogenomics 5, 381-394
56. Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., and Yasui, Y. (2001) Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 93, 1054-1061
57. Ransohoff, D. F. (2007) How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J. Clin. Epidemiol. 60, 1205-1219
58. Syrigos, K. N., Karapanagiotou, E., and Harrington, K. J. (2004) The clinical significance of molecular markers to bladder cancer. Hybrid Hybridomics 23, 335-342
59. Stavropoulos, N. E., Filiadis, I., Ioachim, E., Hastazeris, K., Tsimaris, I., Kalogeras, D., Stefanaki, S., and Agnantis, N. J. (2002) Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer. Anticancer Res. 22, 3759-3764
60. Pfister, C., Moore, L., Allard, P., Larue, H., Lacombe, L., Têtu, B., Meyer, F., and Fradet, Y. (1999) Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin. Cancer Res. 5, 4079-4084
61. Jain, K. K. (2008) Innovations, challenges and future prospects of oncoproteomics. Mol. Oncol. 2, 153-160
62. Zieger, K. (2008) High throughput molecular diagnostics in bladder cancer - on the brink of clinical utility. Mol. Oncol. 1, 384-394
63. Riegman, P. H., Morente, M. M., Betsou, F., de Blasio, P., and Geary, P.; Marble Arch International Working Group on Biobanking for Biomedical Research (2008) Biobanking for better healthcare. Mol. Oncol. 2, 213-222
64. Karni, R., de Stanchina, E., Lowe, S. W., Sinha, R., Mu, D., and Krainer, A. R. (2007) The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 14, 185-193